Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rani Therapeutics HoldingsRANI -5.76%31 3-1 Month Momentum % is -14.36% as of Aug. 01, 2026. GuruFocus rates RANI with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,389 Biotechnology companies, Rani Therapeutics Holdings ranks worse than 59.9% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-01), Rani Therapeutics Holdings's 3-1 Month Momentum % is -14.36%.
The industry rank for Rani Therapeutics Holdings's 3-1 Month Momentum % or its related term are showing as below:
RANI's 3-1 Month Momentum % is ranked worse than 59.9% of 1389
companies
in the Biotechnology industry
Industry Median: -7.65
vs RANI: -14.36
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Rani Therapeutics Holdings 3-1 Month Momentum % Related Terms
RANI vs ONCY, ALDX, COYA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Rani Therapeutics Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings (RANI) has a 3-1 Month Momentum % of -14.36% as of Aug. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Rani Therapeutics Holdings and its competitors. According to the industry distribution chart, Rani Therapeutics Holdings ranks #832 out of 1389 companies in the Biotechnology industry, placing it in the top 59.9%.
Is Rani Therapeutics Holdings' 3-1 Month Momentum % too high?
Rani Therapeutics Holdings' current 3-1 Month Momentum % is -14.36%. Based on the distribution chart, Rani Therapeutics Holdings ranks #832 out of 1389 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rani Therapeutics Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' 3-1 Month Momentum % compare to ONCY and ALDX?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #832 out of 1389 companies for 3-1 Month Momentum %. This places Rani Therapeutics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current 3-1 Month Momentum % is -14.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current 3-1 Month Momentum % of -14.36%. The current 3-1 Month Momentum % is -14.36%. Rani Therapeutics Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current 3-1 Month Momentum % is -14.36% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
31GF Score
Get the complete analysis for RANI
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RANI has been successfully added to your 
